SEC Comment Letter for Telix Pharmaceuticals Ltd (TLX, TLPPF) (CIK 0002007191) (TLX) — Apr 23, 2026

Telix Pharmaceuticals Ltd (TLX, TLPPF) (CIK 0002007191)
Date: April 23, 2026 · CIK: 0002007191 · Accession: 0000000000-26-004147

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-42128

Date

April 23, 2026

Author

Division of

Form

UPLOAD

Company

Telix Pharmaceuticals Ltd (TLX, TLPPF) (CIK 0002007191)

Letter

Re: Telix Pharmaceuticals Limited Form 20-F for Fiscal Year Ended December 31, 2025 File No. 001-42128 Dear Darren Smith:

April 23, 2026

Darren Smith Group Chief Financial Officer Telix Pharmaceuticals Limited 55 Flemington Road North Melbourne, Victoria 3051 Australia

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 April 23, 2026

Darren Smith
Group Chief Financial Officer
Telix Pharmaceuticals Limited
55 Flemington Road
North Melbourne, Victoria 3051
Australia

 Re: Telix Pharmaceuticals Limited
 Form 20-F for Fiscal Year Ended December 31, 2025
 File No. 001-42128
Dear Darren Smith:

 We have completed our review of your filing. We remind you that the
company and its
management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding
any review, comments, action or absence of action by the staff.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
</TEXT>
</DOCUMENT>

SecProbe.io